Table 3 Univariable analysis of possible factors affecting overall survival
| Â | Number of patients (%) | Median OS, months (95% CI) | HR (95% CI) | P value |
|---|---|---|---|---|
Age | ||||
  < 65 | 90 (52.0%) | 10.1 (7.6–11.4) | 1.00 |  |
  ≥ 65 | 83 (48.0%) | 7.2 (6.0–10.0) | 1.28 (0.92–1.78) | 0.138 |
Sex (female/ male) | ||||
 Female | 86 (49.7%) | 10.1 (7.8–12) | 1.00 |  |
 Male | 87 (50.3%) | 7.1 (5.5–10.1) | 1.22 (0.88–1.69) | 0.234 |
ECOG | ||||
 0–1 | 164 (94.8%) | 8.1 (7.1–10.3) | 1.00 |  |
 2 | 9 (5.2%) | 7.5 (2.8-NE) | 1.86 (0.94–3.68) | 0.074 |
BMI | ||||
  > 25 | 136 (78.6%) | 7.8 (6.6–9.7) | 1.00 |  |
  ≥ 25 | 37 (21.4%) | 11.9 (7.1–15.1) | 0.79 (0.53–1.18) | 0.255 |
Stage | ||||
 IIIB/ IVA | 9 (5.2%) | 7.2 (2.1-NE) | 1.00 |  |
 IVB | 164 (94.8%) | 8.1 (7.1–10.3) | 0.68 (0.35–1.35) | 0.272 |
Charlson comorbidity index | ||||
  < 9 | 110 (63.6%) | 9.7 (7.8–11.0) | 1.00 |  |
  ≥ 9 | 63 (36.4%) | 6.4 (4.4–10.2) | 1.23 (0.87–1.72) | 0.237 |
Local invasion | ||||
 Liver | 47 (27.2%) | 7.7 (6.6–11.4) | 1.47 (1.02–2.12) | 0.040 |
 Extrahepatic bile duct | 26 (15.0%) | 6.5 (5.0–11.9) | 1.06 (0.67–1.67) | 0.812 |
 Intestine | 20 (11.6%) | 8.6 (5.0-NE) | 0.79 (0.47–1.34) | 0.386 |
 Peritoneum | 2 (1.2%) | 10.5 (2.3-NE) | 0.94 (0.23–3.82) | 0.933 |
 Hepatic artery | 15 (8.7%) | 6.4 (5.0-NE) | 1.12 (0.63–1.98) | 0.699 |
 Portal vein | 11 (6.4%) | 5.9 (2.3-NE) | 1.17 (0.6–2.31) | 0.643 |
Metastasis site | ||||
 Liver | 74 (42.8%) | 6.2 (5.3–10.0) | 1.72 (1.23–2.41) | 0.002 |
 Peritoneum | 46 (26.6%) | 6.5 (4.2–10.1) | 1.25 (0.87–1.82) | 0.229 |
 Lung | 29 (16.8%) | 7.2 (5.4–15.6) | 0.85 (0.54–1.34) | 0.487 |
 Bone or muscular system | 14 (8.1%) | 5.1 (3.3–13.1) | 2.03 (1.14–3.61) | 0.016 |
 Distant lymph node | 102 (59.0%) | 8.3 (6.5–10.9) | 1.10 (0.79–1.54) | 0.560 |
Total bilirubin | ||||
  ≤ 1.5 X ULN | 130 (75.1%) | 9.7 (7.8–11.0) | 1.00 |  |
  > 1.5 X ULN | 43 (24.9%) | 5.3 (3.7–9.5) | 1.77 (1.21–2.58) | 0.003 |
Transaminase | ||||
  ≤ 1.5 X ULN | 120 (69.4%) | 9.7 (7.8–11.5) | 1.00 |  |
  > 1.5 X ULN | 53 (30.6%) | 6.2 (4.5–9.7) | 1.53 (1.07–2.18) | 0.019 |
NLR | ||||
  ≤ 3 | 75 (43.4%) | 12.4 (10.2–14.6) | 1.00 |  |
  > 3 | 98 (56.6%) | 6.2 (4.8–7.8) | 2.34 (1.66–3.29) | < 0.001 |
PLR | ||||
  < 190 | 102 (59.0%) | 10.3 (9.4–13.7) | 1.00 |  |
  ≥ 190 | 71 (41.0%) | 6.6 (5.6–8.1) | 1.77 (1.27–2.47) | 0.001 |
CEA, ng/mL | ||||
  < 5 | 103 (59.5%) | 10.3 (7.8–13.1) | 1.00 |  |
  ≥ 5 | 70 (40.5%) | 6.5 (5.0–8.1) | 1.87 (1.33–2.63) | < 0.001 |
CA 19–9, U/mL | ||||
  < 500 | 114 (65.9%) | 10.7 (9.0–13.3) | 1.00 |  |
  ≥ 500 | 59 (34.1%) | 5.5 (4.1–7.6) | 2.28 (1.61–3.23) | < 0.001 |